ONCSQ / OncoSec Medical Incorporated - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

US68234L4059 / ONCOSEC MEDICAL INC / SZOP MULTISTRAT LP Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Oncosec Medical Incorporated (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 68234L405 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 ONCOSEC MEDICAL INCOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 ONCOSEC MEDICAL INCOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 ONCOSEC MEDICAL INCOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 ONCOSEC MEDICAL INCORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

US68234L4059 / ONCOSEC MEDICAL INC / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* OncoSec Medical Incorporated (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68234L405 (CUSIP Number) May 16, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.

US68234L4059 / ONCOSEC MEDICAL INC / SZOP Multistrat Management LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* Oncosec Medical Incorporated (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 68234L405 (CUSIP Number) May 16, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 ONCOSEC MEDICAL INCORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Exhibit 99.1 OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules EWING, NJ and SAN DIEGO, CA, May 16, 2023 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient’s immune system to target cancer cells and eradicate

1,408,384 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-260850 Prospectus Supplement (to Prospectus dated November 15, 2021) 1,408,384 Shares of Common Stock We are offering 1,408,384 shares of our common stock, par value $0.0001 per share (“Common Stock”), to certain investors pursuant to this prospectus supplement and the accompanying prospectus. Such investors will also receive unregistered commo

PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ONCOSEC MEDICAL INCORPORATED Warrant Shares: _______ Issue Date: May 18, 2023 Initial Exercise Date: May 18, 2023

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 16, 2023, between OncoSec Medical Incorporated, a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition

COMMON STOCK PURCHASE WARRANT ONCOSEC MEDICAL INCORPORATED Warrant Shares: _______ Issue Date: __________, 2023 Initial Exercise Date: _____________, 2023

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Exhibit 99.2 OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules EWING, NJ and SAN DIEGO, CA, May 18, 2023 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient’s immune system to target cancer cells and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 ONCOSEC MEDICAL INCORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program

Exhibit 99.1 OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program EWING, NJ and SAN DIEGO, CA, May 16, 2023 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient’s immune system to target cancer cells and eradicate disea

EX-99.1

Exhibit 99.1

OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program

Exhibit 99.2 OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program EWING, NJ and SAN DIEGO, CA, April 27, 2023 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 ONCOSEC MEDICAL INCO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

US68234L4059 / ONCOSEC MEDICAL INC / Lind Global Fund II LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* OncoSec Medical Incorporated (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68234L405 (CUSIP Number) April 13, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.0001 per share, OncoSec Medical Incorporated, shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. April 17, 2023 LIND GLOBAL FUND II LP By: Lind Global Partners II

OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Exhibit 99.1 OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules EWING, NJ and SAN DIEGO, CA, April 10, 2023 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient’s immune system to target cancer cells and eradicate d

1,582,932 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-260850 Prospectus Supplement (to Prospectus dated November 15, 2021) 1,582,932 Shares of Common Stock We are offering 1,582,932 shares of our common stock, par value $0.0001 per share (“Common Stock”) to certain investors pursuant to this prospectus supplement and the accompanying prospectus. Such investors will also receive unregistered common

OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Exhibit 99.2 OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules EWING, NJ and SAN DIEGO, CA, April 11, 2023 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient’s immune system to target cancer cells and

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 10, 2023, between OncoSec Medical Incorporated, a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi

COMMON STOCK PURCHASE WARRANT ONCOSEC MEDICAL INCORPORATED

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ONCOSEC MEDICAL INCORPORATED

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 ONCOSEC MEDICAL INCO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

OncoSec Medical Incorporated 820 Bear Tavern Road Ewing, New Jersey 08628 April 10, 2023

OncoSec Medical Incorporated 820 Bear Tavern Road Ewing, New Jersey 08628 April 10, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA

Exhibit 99.1 OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment EWING, NJ and SAN DIEGO, CA, April 3, 2023 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immun

As filed with the Securities and Exchange Commission on April 3, 2023

As filed with the Securities and Exchange Commission on April 3, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 ONCOSEC MEDICAL INCOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) OncoSec Medical Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $0.

Power of Attorney (incorporated by reference to the signature page of the Registration Statement on Form S-1, filed on March 28, 2023).

As filed with the Securities and Exchange Commission on March 27, 2023 Registration No.

Form of Pre-Funded Warrant (current offering)

Exhibit 4.5 Pre-Funded WARRANT To purchase Shares of Common Stock ONCOSEC MEDICAL INCORPORATED Warrant Shares: Initial Exercise Date: [ ], 2023 THIS Pre-Funded WARRANT to Purchase Shares of Common Stock (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at

Form of Common Stock Purchase Warrant (current offering)

Exhibit 4.6 COMMON STOCK PURCHASE WARRANT ONCOSEC MEDICAL INCORPORATED Warrant Shares: Issue Date: [ ], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after the date hereof (the “Initia

Form of Securities Purchase Agreement (current offering)

Exhibit 10.28 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of [ ], 2023, between OncoSec Medical Incorporated, a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions

Form of Placement Agent Agreement

Exhibit 1.1 [ ], 2023 OncoSec Medical Incorporated 820 Bear Tavern Road Ewing, NJ 08628 Attn: Chief Executive Officer Dear Mr. Arch: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and OncoSec Medical Incorporated, a company incorporated under the laws of the State of Nevada (the “Company”), that the Place

Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 000-54318 ONCOSEC MEDICAL INCORP

OncoSec Medical Incorporated 820 Bear Tavern Road Ewing, New Jersey 08628 February 28, 2023

OncoSec Medical Incorporated 820 Bear Tavern Road Ewing, New Jersey 08628 February 28, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 ONCOSEC MEDICAL I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

US68234L4059 / ONCOSEC MEDICAL INC / Avidity Partners Management LP Passive Investment

SC 13G/A 1 d994090313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Oncosec Medical Incorporated (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68234L405 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the

Form of Pre-Funded Warrant (current offering)

Exhibit 4.5 Pre-Funded WARRANT To purchase Shares of Common Stock ONCOSEC MEDICAL INCORPORATED Warrant Shares: Initial Exercise Date: [ ], 2023 THIS Pre-Funded WARRANT to Purchase Shares of Common Stock (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at

As filed with the Securities and Exchange Commission on February 1, 2023

As filed with the Securities and Exchange Commission on February 1, 2023 Registration No.

Lease Agreement, dated September 6, 2022, between OncoSec Medical Incorporated and Mountain View Office Park, L.L.C. (incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q).

Exhibit 10.26 LEASE OF BUSINESS PREMISES TABLE OF CONTENTS ARTICLE 1. Use of Demised Premises 3 ARTICLE 2. Events of Default; Remedies 3 ARTICLE 3. Assignment or Subletting 4 ARTICLE 4. Alterations and Improvements 4 ARTICLE 5. Mechanic’s Lien 4 ARTICLE 6. Glass Damage 5 ARTICLE 7. Limitation of Liability 5 ARTICLE 8. Utilities, Services, Maintenance Charges 5 ARTICLE 9. Inspections, Right of Entr

Form of Placement Agent Agreement

Exhibit 1.1 [ ], 2023 OncoSec Medical Incorporated 820 Bear Tavern Road Ewing, NJ 08628 Attn: Chief Executive Officer Dear Mr. Arch: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and OncoSec Medical Incorporated, a company incorporated under the laws of the State of Nevada (the “Company”), that the Place

Form of Common Stock Purchase Warrant (current offering)

Exhibit 4.6 COMMON STOCK PURCHASE WARRANT ONCOSEC MEDICAL INCORPORATED Warrant Shares: Issue Date: [ ], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after the date hereof (the “Initia

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) OncoSec Medical Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $0.

OncoSec Medical Incorporated 820 Bear Tavern Road Ewing, NJ 08628

CORRESP 1 filename1.htm OncoSec Medical Incorporated 820 Bear Tavern Road Ewing, NJ 08628 February 1, 2023 Via EDGAR Mr. Frank Wyman Ms. Angela Connell Division of Corporation Finance Securities and Exchange Commission Washington, D.C. 20549 Re: OncoSec Medical Incorporated Form 10-K for Fiscal Year Ended July 31, 2022 Filed October 31, 2022 File No. 000-54318 Dear Mr. Wyman and Ms. Connell: OncoS

Form of Securities Purchase Agreement (current offering)

Exhibit 10.27 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of [ ], 2023, between OncoSec Medical Incorporated, a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Certificate of Amendment to the Articles of Incorporation, as amended, of OncoSec Medical Incorporated (incorporated by reference to Exhibit 3.1 on our Current Report on Form 8-K, filed on January 4, 2023).

Exhibit 3.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2022 ONCOSEC MEDICAL I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2022 ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 000-54318 ONCOSEC MEDICAL INCORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Form of Common Stock Purchase Warrant, dated November 30, 2022 (incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K, filed on December 1, 2022).

Exhibit 4.2 COMMON STOCK PURCHASE WARRANT ONCOSEC MEDICAL INCORPORATED Warrant Shares: Issue Date: December 1, 2022 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after December 1, 2022 (the

Form of Pre-Funded Warrant, dated November 30, 2022 (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K, filed on December 1, 2022).

Exhibit 4.1 Pre-Funded WARRANT To purchase Shares of Common Stock ONCOSEC MEDICAL INCORPORATED Warrant Shares: Initial Exercise Date: December 1, 2022 THIS Pre-Funded WARRANT to Purchase Shares of Common Stock (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 30, 2022 ONCOSEC MEDICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 30, 2022 ONCOSEC MEDICAL INCORPORATED (Exact name of Registrant as specified in its charter) Nevada 000-54318 98-0573252 (State or other jurisdiction of incorporation) (Commi

Form of Voting Agreement

Exhibit 10.3 VOTING AGREEMENT This Voting Agreement (this “Voting Agreement”) is being delivered to you in connection with an understanding by and between OncoSec Medical Incorporated, a Nevada corporation (the “Company”), and the person or persons named on the signature pages hereto (collectively, the “Holder”). Reference is hereby made to the public offering (the “Offering”) of securities of the

OncoSec Announces Pricing of $3.5 Million Public Offering

Exhibit 99.1 OncoSec Announces Pricing of $3.5 Million Public Offering PENNINGTON, N.J. and SAN DIEGO, November 30, 2022 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient’s own immune system to target and eradicate cancer, today announced the pri

OncoSec Medical Incorporated 1,166,667 Shares of Common Stock 1,166,667 Pre-Funded Warrants 1,166,667 Common Warrants

PROSPECTUS Registration Statement No. 333-268081 Filed Pursuant to Rule 424(b)(3) OncoSec Medical Incorporated 1,166,667 Shares of Common Stock 1,166,667 Pre-Funded Warrants 1,166,667 Common Warrants We are offering (i) 1,166,667 shares of common stock of OncoSec Medical Incorporated (the ?Common Stock?), and (ii) Common Warrants to purchase 1,166,667 shares of common stock (?Common Warrants?), at

Form of Securities Purchase Agreement, dated November 30, 2022 (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K, filed on December 1, 2022).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 30, 2022, between OncoSec Medical Incorporated, a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond

Placement Agency Agreement.

Exhibit 10.2 November 30, 2022 OncoSec Medical Incorporated 24 North Main Street Pennington, NJ 08534 Attn: Chief Executive Officer Dear Mr. Arch: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and OncoSec Medical Incorporated, a company incorporated under the laws of the State of Nevada (the “Company”),

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2022 ONCOSEC MEDICAL I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

As filed with the Securities and Exchange Commission on November 29, 2022

As filed with the Securities and Exchange Commission on November 29, 2022 Registration No.

Form of Securities Purchase Agreement issued in connection with this Offering.

Exhibit 4.6 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of [ ], 2022, between OncoSec Medical Incorporated, a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se

Form of Common Stock Warrant issued in connection with this Offering.

Exhibit 4.7 COMMON STOCK PURCHASE WARRANT ONCOSEC MEDICAL INCORPORATED Warrant Shares: Issue Date: [ ], 2022 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after [ ], 2022 (the “Initial Exer

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) OncoSec Medical Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Fees Previously Paid Equity Common Stock, $0.

OncoSec Medical Incorporated 24 North Main Street Pennington, NJ 08534 (855) 622-6732

OncoSec Medical Incorporated 24 North Main Street Pennington, NJ 08534 (855) 622-6732 November 29, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.

Convertible Promissory Note and Security Agreement dated November 25, 2022 (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed on November 29, 2022).

Exhibit 10.1 Execution Version THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF OR UPON THE CONVERSION OF ACCRUED INTEREST AS FURTHER DESCRIBED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR PURSUANT TO AN EXEM

OncoSec Medical Incorporated 24 North Main Street Pennington, New Jersey 08534 November 28, 2022

OncoSec Medical Incorporated 24 North Main Street Pennington, New Jersey 08534 November 28, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

***

PROCOPIO 12544 High Bluff Drive Suite 400 San Diego, CA 92130 T. 858.720.6300 F. 619.235.0398 DEL MAR HEIGHTS Las Vegas Orange County SAN DIEGO scottsdale SILICON VALLEY washington d.c. November 28, 2022 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jason Drory Laura Crotty Re: OncoSec

Form of Certificate of Amendment to the Articles of Incorporation of OncoSec Medical Incorporated

Exhibit 3.7

As filed with the Securities and Exchange Commission on November 28, 2022

As filed with the Securities and Exchange Commission on November 28, 2022 Registration No.

Form of Placement Agent Agreement

Exhibit 1.1 [ ], 2022 OncoSec Medical Incorporated 24 North Main Street Pennington, NJ 08534 Attn: Chief Executive Officer Dear Mr. Arch: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and OncoSec Medical Incorporated, a company incorporated under the laws of the State of Nevada (the “Company”), that the

OncoSec Medical Incorporated 24 North Main Street Pennington, NJ 08534 (855) 622-6732

OncoSec Medical Incorporated 24 North Main Street Pennington, NJ 08534 (855) 622-6732 November 23, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.

Form of Series B Common Stock Warrant issued in connection with this Offering.

Exhibit 4.7 COMMON STOCK PURCHASE WARRANT ONCOSEC MEDICAL INCORPORATED Warrant Shares: Issue Date: [ ], 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after the Stockholder Approval Dat

Form of Pre-Funded Warrant issued in connection with this Offering (incorporated by reference to Exhibit 4.4 of our Registration Statement on Form S-1, filed on November 23, 2022).

Exhibit 4.4 Pre-Funded WARRANT To purchase Shares of Common Stock ONCOSEC MEDICAL INCORPORATED Warrant Shares: Initial Exercise Date: [ ], 2022 THIS Pre-Funded WARRANT to Purchase Shares of Common Stock (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at

As filed with the Securities and Exchange Commission on November 23, 2022

As filed with the Securities and Exchange Commission on November 23, 2022 Registration No.

Form of Series A Common Stock Warrant issued in connection with this Offering.

Exhibit 4.5 COMMON STOCK PURCHASE WARRANT ONCOSEC MEDICAL INCORPORATED Warrant Shares: Issue Date: [ ], 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after the Stockholder Approval Dat

Form of Securities Purchase Agreement issued in connection with this Offering.

Exhibit 4.6 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is dated as of [ ], 2022, between OncoSec Medical Incorporated, a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions se

Form of Lock-Up Agreement (incorporated by reference to Exhibit 4.9 of our Registration Statement on Form S-1, filed on November 23, 2022)

Exhibit 4.9 LOCK-UP AGREEMENT November , 2022 Re: Securities Purchase Agreement, dated as of November , 2022 (the ?Purchase Agreement?), between OncoSec Medical Incorporated (the ?Company?) and the purchasers signatory thereto Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the ?Letter Agreement?) shall have the meanings set forth in the Purchase Agreement. The

From of Voting Agreement (incorporated by reference to Exhibit 4.8 of our Registration Statement on Form S-1, filed on November 23, 2022)

Exhibit 4.8 VOTING AGREEMENT This Voting Agreement (this ?Voting Agreement?) is being delivered to you in connection with an understanding by and between OncoSec Medical Incorporated, a Nevada corporation (the ?Company?), and the person or persons named on the signature pages hereto (collectively, the ?Holder?). Reference is hereby made to the public offering (the ?Offering?) of securities of the

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) OncoSec Medical Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Fees Previously Paid Equity Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 ONCOSEC MEDICAL I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Investor Presentation of OncoSec Medical Incorporated dated November 22, 2022.

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 ONCOSEC MEDICAL I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma

Exhibit 99.1 OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma PENNINGTON, NJ and SAN DIEGO, CA, November XX, 2022 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a clinical stage biotechnology company developing intratumoral immunotherapies that stimulate the patient’s immune system to target ca

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Filing Fee Table

EX-FILING FEES 3 ex-107.htm CALCULATION OF FILING FEE TABLES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) OncoSec Medical Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Proposed Maximum

OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

Exhibit 99.1 OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda?) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment PENNINGTON, NJ and SAN DIEGO, CA, November 11, 2022 /PRNewswire/ ? OncoSec Medical Incorporated (NASDAQ: ONCS) (the ?Company? or ?OncoSec?), a clinical-stage biotechnology company developi

***

PROCOPIO 12544 High Bluff Drive Suite 400 San Diego, CA 92130 T. 858.720.6300 F. 619.235.0398 DEL MAR HEIGHTS Las Vegas Orange County SAN DIEGO scottsdale SILICON VALLEY washington d.c. November 14, 2022 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jason Drory Laura Crotty Re: OncoSec

As filed with the Securities and Exchange Commission on November 14, 2022

As filed with the Securities and Exchange Commission on November 14, 2022 Registration No.

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 8, 2022 (November 9, 2022) ONCOSEC MEDICAL INCORPORATED (Exact name of registrant as specified in its charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Inc

Certificate of Change to amend the Articles of Incorporation of OncoSec Medical Incorporated, as filed with the Nevada Secretary of State on November 1, 2022 (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed November 8, 2022.

Exhibit 3.1

OncoSec Announces Reverse Stock Split

Exhibit 99.1 OncoSec Announces Reverse Stock Split November 8, 2022 PENNINGTON, N.J. and SAN DIEGO, November 8, 2022/PRNewswire/ ? OncoSec Medical Incorporated (NASDAQ: ONCS) (the ?Company? or ?OncoSec?), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient?s own immune system to target and eradicate cancer, today announced it intends t

As filed with the Securities and Exchange Commission on November 1, 2022

As filed with the Securities and Exchange Commission on November 1, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) OncoSec Medical Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 000-54318 ONCOSEC MEDICAL I

Amended and Restated Bylaws of OncoSec Medical Incorporated (incorporated by reference to Exhibit 3.4 on our Annual Report on Form 10-K, filed on October 31, 2022).

Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF ONCOSEC MEDICAL INCORPORATED TABLE OF CONTENTS Page ARTICLE 1 OFFICES 1 Section 1.1 Principal Office 1 Section 1.2 Other Offices 1 ARTICLE 2 STOCKHOLDERS? MEETINGS 1 Section 2.1 Place of Meetings 1 Section 2.2 Annual Meetings 1 Section 2.3 Special Meetings 2 Section 2.4 Notice of Meetings 2 Section 2.5 Quorum and Voting 2 Section 2.6 Voting Rights 3 Secti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2022 ONCOSEC MEDICAL IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

OncoSec Announces Pipeline Prioritization and Workforce Reduction

Exhibit 99.1 OncoSec Announces Pipeline Prioritization and Workforce Reduction PENNINGTON, NJ and SAN DIEGO, CA, October 4, 2022 /PRNewswire/ ? OncoSec Medical Incorporated (NASDAQ: ONCS) (the ?Company? or ?OncoSec?), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient?s own immune system to target and eradicate cancer, today announced

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) OncoSec Medical Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

As filed with the Securities and Exchange Commission on July 29, 2022

As filed with the Securities and Exchange Commission on July 29, 2022 Registration No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 000-54318 ONCOSEC MEDICAL INCORPOR

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A 1 formdef14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer

Exhibit 99.1 OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer PENNINGTON, NJ and SAN DIEGO, CA, April 29, 2022 /PRNewswire/ ? OncoSec Medical Incorporated (NASDAQ: ONCS) (the ?Company? or ?OncoSec?), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body?s immune system to target and attack cancer, today announced th

Executive Employment Agreement between OncoSec Medical Incorporated and Robert H. Arch, dated April 28, 2022 (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K, filed on April 29, 2022).

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT dated as of April 28, 2022, and effective as of May 2, 2022 (the ?Effective Date?) between OncoSec Medical Incorporated (the ?Company?), a Nevada corporation, and Robert H. Arch (the ?Executive?). Recital: The parties desire to enter into this Agreement so as to provide for the employment of the Executive by the Company and for certa

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2022 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission Fi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 ONCOSEC MEDICAL INCORPORATED (Exact name of registrant as specified in its charter) Nevada 000-54318 98-0573252 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2022 ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 000-54318 ONCOSEC MEDICAL INCORP

OncoSec Medical Incorporated 2015 Employee Stock Purchase Plan

Exhibit 10.1 ONCOSEC MEDICAL INCORPORATED 2015 EMPLOYEE STOCK PURCHASE PLAN (as adopted by the Board of Directors on October 14, 2015 and proposed to be adopted by the Shareholders on December 4, 2015) 1. ESTABLISHMENT, PURPOSE, AND TIME OF PLAN. 1.1. Establishment. The OncoSec Medical Incorporated 2015 Employee Stock Purchase Plan (the ?Plan?) is hereby established effective as of the date of its

OncoSec Announces Appointment of George Chi as Chief Financial Officer

Exhibit 99.1 OncoSec Announces Appointment of George Chi as Chief Financial Officer PENNINGTON, NJ and SAN DIEGO, CA, February 22, 2022 /PRNewswire/ ? OncoSec Medical Incorporated (NASDAQ: ONCS) (the ?Company? or ?OncoSec?), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body?s immune system to target and attack cancer, today announced th

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 ONCOSEC MEDICAL INCORPORATED (Exact name of registrant as specified in its charter) Nevada 000-54318 98-0573252 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Offer Letter between OncoSec Medical Incorporated and George Chi, dated January 28, 2022 (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K, filed on February 22, 2022).

Exhibit 10.1 January 28, 2022 Mr. George Chi 618 Ellington Road Ridgewood, NJ 07450 Dear Mr. Chi: On behalf of OncoSec Medical Incorporated (the ?Company? or ?OncoSec?), I am very pleased to offer you the position of Chief Financial Officer of the Company. This letter establishes the terms of your employment with the Company if you accept this offer. If you accept this offer of employment, your ef

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2022 ONCOSEC MEDICAL INCORPORATED (Exact name of registrant as specified in its charter) Nevada 000-54318 98-0573252 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

ONCS / OncoSec Medical Inc / Avidity Partners Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2021 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commissio

Amended and Restated Bylaws of the Company

EX-3.2 3 ex3-2.htm Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ONCOSEC MEDICAL INCORPORATED TABLE OF CONTENTS Page ARTICLE 1 OFFICES 1 Section 1.1 Principal Office 1 Section 1.2 Other Offices 1 ARTICLE 2 STOCKHOLDERS’ MEETINGS 1 Section 2.1 Place of Meetings 1 Section 2.2 Annual Meetings 2 Section 2.3 Special Meetings 2 Section 2.4 Notice of Meetings 2 Section 2.5 Quorum and Voting 3 Section 2.6 Vo

Amendment to the Company’s Amended and Restated Bylaws

Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF ONCOSEC MEDICAL INCORPORATED THIS AMENDMENT TO THE BYLAWS OF ONCOSEC MEDICAL INCORPORATED (this ?Amendment?) is made effective as of December 15, 2021 (the ?Effective Date?), and amends the amended and restated bylaws (the ?Bylaws?) of OncoSec Medical Incorporated, a Nevada corporation (the ?Company?). WHEREAS, pursuant to Article 10 of t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2021 ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 000-54318 ONCOSEC MEDICAL INCORP

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 8, 2021 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 23, 2021 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commissio

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2021 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commissio

OncoSec Medical Incorporated

OncoSec Medical Incorporated November 12, 2021 Securities and Exchange Commission Department of Corporation Finance Washington, D.

Form of Indenture †

Exhibit 4.1 ONCOSEC MEDICAL INCORPORATED FORM OF INDENTURE Dated as of [ ], 20[ ] DEBT SECURITIES [] Trustee CROSS REFERENCE SHEET Cross-reference sheet of provisions of the Trust Indenture Act of 1939 and this indenture* Trust Indenture Act Section Indenture Section ?310 (a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.05(1), 16.02 (b)(1) 11.04(b), 16.02 ?311 11.01(f), 16.02 ?312 14.02(d), 16.02 (b

As filed with the Securities and Exchange Commission on November 5, 2021

As filed with the Securities and Exchange Commission on November 5, 2021 Registration No.

Description of Securities of OncoSec Medical Incorporated (incorporated by reference to Exhibit 4.3 on our Form 10-K, filed on October 29, 2021).

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 When used herein, the terms ?we,? ?our,? and ?us? refer to OncoSec Medical Incorporated DESCRIPTION OF CAPITAL STOCK General Pursuant to our articles of incorporation, we are currently authorized to issue 100,000,000 shares of common stock, par value $0.0001 per share. As

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 000-54318 ONCOSEC MEDICAL I

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 16, 2021 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission

Separation Agreement between OncoSec Medical Incorporated and Mr. Leuthner, dated August 13, 2021 (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K, filed on August 16, 2021).

Exhibit 10.1 SEPARATION AGREEMENT THIS AGREEMENT (the ?Agreement?) is entered into as of the Effective Date, as defined in Paragraph 6 hereof, by and between OncoSec Medical Incorporated (the ?Company?) and Brian A. Leuthner (?Employee?). Together, the Company and Employee may be referred to hereinafter as the ?Parties?. In consideration of the payments, covenants and releases described below, and

Separation Agreement between OncoSec Medical Incorporated and Mr. O’Connor, dated June 24, 2021 (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K, filed on June 24, 2021).

Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT THIS CONFIDENTIAL SEPARATION AGREEMENT (the ?Agreement?) is entered into as of June 24, 2021, to be effective as of the Effective Date, as defined in Paragraph 8 hereof, by and between OncoSec Medical Incorporated (the ?Company?) and Daniel J. O?Connor (?Executive?). Together, the Company and Executive may be referred to hereinafter as the ?Parties.?

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2021 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-54318 (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2021 [ ] TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 000-54318 ONCOSEC MEDICAL INCO

As filed with the Securities and Exchange Commission on June 11, 2021.

As filed with the Securities and Exchange Commission on June 11, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OncoSec Medical Incorporated (Exact name of registrant as specified in its charter) Nevada 98-0573252 (State or other jurisdiction of (I.R.S. Employer incorporation or orga

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 29, 2021 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission F

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Amendment to the OncoSec Medical Incorporated 2011 Stock Incentive Plan (incorporated by reference to Exhibit A to the Company’s Proxy Statement on Schedule 14A, filed on March 18, 2021)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Co-Promotion Agreement, dated January 19, 2021, by and between OncoSec Medical Incorporated and Sirtex Medical, Inc.†

Exhibit 10.1 EXECUTION COPY Portions of this document have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. Redacted portions are indicated with the notation ?[***].? CO-PROMOTION AGREEMENT This CO-PROMOTION AGREEMENT (this ?Agreement?) is entered into as of January 15, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2021 [ ] TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 000-54318 ONCOSEC MEDICAL IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 8 SCHEDULE 13D Under the Securities Exchange Act of 1934 ONCOSEC MEDICAL INCORPORATED (Name of Issuer) Common Stock ($0.0001 par value per share) (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 8 to SCHEDULE 13D Under the Securities Exchange Act of 1934 ONCOSEC MEDICAL INCORPORATED (Name of Issuer) Common Stock ($0.0001 par value per share) (Title of Class of Securities) 68234L207 (CUSIP Number) Hee Do Koo CEO Alpha Holdings, Inc. Gangnam-gu Seolleung-ro 119-Gil 31 Seoul, KOREA +82-2-517-8841 With a cop

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

Altium Capital Management, LP SC 13G/A EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2 )*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2 )* OncoSec Medical Incorporated (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68234L306 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 2, 2021 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission

Entry into a Material Definitive Agreement, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 21, 2021 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-54318 (Commission File Numbe

7,711,284 Shares of Common Stock OncoSec Medical Incorporated

Filed Pursuant to Rule 424(b)(5) Registration No. 333-233447 PROSPECTUS SUPPLEMENT To the Prospectus dated June 26, 2020) 7,711,284 Shares of Common Stock OncoSec Medical Incorporated We are offering 7,711,284 shares of our common stock, par value $0.0001 per share, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Capital Market under

Underwriting Agreement, dated January 21, 2021, between OncoSec Medical Incorporated and BTIG, LLC, as representative of the several underwriters named therein.

Exhibit 1.1 EXECUTION VERSION 7,711,284 Shares ONCOSEC MEDICAL INCORPORATED Common Stock UNDERWRITING AGREEMENT January 21, 2021 BTIG, LLC As Representative of the several Underwriters 600 Montgomery Street San Francisco, California 94111 Dear Ladies and Gentlemen: 1. Introductory. OncoSec Medical Incorporated, a Nevada corporation (the “Company”), proposes to sell, pursuant to the terms of this A

Subject to completion, dated January 20, 2021

Filed Pursuant to Rule 424(b)(5) Registration No. 333-233447 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a

-

As filed with the Securities and Exchange Commission on January 20, 2021 Registration No.

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™ Sirtex to Pay $5 Million for a Non-Exclusive Option to Co-Promote TAVO in Patients with Checkpoint Refractory Metastatic Melanoma in the U.S. and an Additional $25 Million i

Exhibit 99.1 OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™ Sirtex to Pay $5 Million for a Non-Exclusive Option to Co-Promote TAVO in Patients with Checkpoint Refractory Metastatic Melanoma in the U.S. and an Additional $25 Million if the Option is Exercised PENNINGTON, N.J. and SAN DIEGO, January 19, 2021 /PRNewswire/ - OncoSec Medical Incorporated (NASDAQ:ONCS) (the

Entry into a Material Definitive Agreement, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 19, 2021 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Second Amendment to Agreement of Lease, dated August 25, 2020, by and between Mawlt, Inc. and OncoSec Medical Incorporated

Exhibit 10.1

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 000-54318 ONCOSEC MEDICAL IN

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 000-5

ONCS / OncoSec Medical Incorporated / Alpha Holdings, Inc. - AMENDMENT NO.7 TO SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 7 to SCHEDULE 13D Under the Securities Exchange Act of 1934 ONCOSEC MEDICAL INCORPORATED (Name of Issuer) Common Stock ($0.0001 par value per share) (Title of Class of Securities) 68234L207 (CUSIP Number) Hee Do Koo CEO Alpha Holdings, Inc. Gangnam-gu Apgujeong-ro 62-gil 17-10 Seoul, KOREA +82-2-517-8841 With a c

Other Events, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2020 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission

OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020 — 30% overall response rate (ORR) and 6% complete response (CR) rate achieved — — 35% ORR achieved in patients with Sta

Exhibit 99.1 OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020 — 30% overall response rate (ORR) and 6% complete response (CR) rate achieved — — 35% ORR achieved in patients with Stage IV M1c or M1d disease — — TAVO + pembrolizumab demonstrated durable responses for up to two years — — Data selected for Poster Walk di

OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19 — First next-generation DNA vaccine candidate to deliver spike (S) protein from SARS-CoV-2 plus immune-stimulat

Exhibit 99.1 OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19 — First next-generation DNA vaccine candidate to deliver spike (S) protein from SARS-CoV-2 plus immune-stimulating interleukin-12 (IL-12) to elicit T-cell activation and drive robust humoral immunity — — Providence St. Joseph Health, one of the nat

Other Events, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2020 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 000-54318 ONCOSEC MEDIC

Description of Securities of OncoSec Medical Incorporated.

Exhibit 4.15 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 When used herein, the terms “we,” “our,” and “us” refer to OncoSec Medical Incorporated DESCRIPTION OF CAPITAL STOCK General Pursuant to our articles of incorporation, we are currently authorized to issue 100,000,000 shares of common stock, par value $0.0001 per share. A

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2020 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 16, 2020 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction (Commission (IRS Employer of I

Placement Agency Agreement entered into by and among OncoSec Medical Incorporated, ThinkEquity, a division of Fordham Financial Management, Inc. and Torreya Capital LLC on August 16, 2020.

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of August 16, 2020, is by and among OncoSec Medical Incorporated, a Nevada corporation with headquarters located at 24 North Main Street, Pennington, NJ 08534-2218 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collecti

Form of Securities Purchase Agreement.

EX-10.1 3 ex10-1.htm Exhibit 10.1 PLACEMENT AGENCY AGREEMENT August 16, 2020 ThinkEquity, a division of Fordham Financial Management, Inc. 17 State Street, 22nd Floor New York, NY 10004 Torreya Capital, LLC 555 Madison Avenue, Suite 1201 New York • NY 10022 Ladies and Gentlemen: Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division

Prospectus Supplement dated August 17, 2020. TABLE OF CONTENTS

Filed Pursuant to Rule 424(b)(5) Registration No. 333-233447 PROSPECTUS SUPPLEMENT (To the Prospectus dated June 26, 2020) 4,608,589 Shares Common Stock OncoSec Medical Incorporated We are offering 4,608,589 shares of our common stock, par value $0.0001 per share, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Capital Market under t

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 21, 2020 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission Fi

-

ONCOSEC MEDICAL INCORPORATED 24 North Main Street Pennington, NJ 08534-2218 June 24, 2020 Securities and Exchange Commission Department of Corporation Finance Washington, D.

-

As filed with the Securities and Exchange Commission on June 22, 2020 Registration No.

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 000-54318 ONCOSEC MEDICAL INCO

Certificate of Amendment of Amended and Restated Articles of Incorporation of OncoSec Medical Incorporated (incorporated by reference to Exhibit 3.1 on our Current Report on Form 8-K, filed on May 29, 2020).

Exhibit 3.1 ATTACHMENT TO CERTIFICATE OF AMENDMENT FOR ONCOSEC MEDICAL INCORPORATED Article 3. Authorized Shares. Article 3 of the Articles of Incorporation of the Corporation is hereby amended to read in its entirety as follows: “The number of shares the corporation is authorized to issue is 100,000,000 authorized shares of common stock, par value $0.0001 per share.” Article 6. That the Articles

Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 29, 2020 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-54318 (Commission File Number) 9

-

As filed with the Securities and Exchange Commission on May 29, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OncoSec Medical Incorporated (Exact name of registrant as specified in its charter) Nevada 98-0573252 (State or other jurisdiction of (I.R.S. Employer incorporation or organ

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

First Amendment to the Executive Employment Agreement entered into between the Company and Daniel J. O’Connor, dated November 7, 2017, as filed with the Securities and Exchange Commission on November 9, 2017, as Exhibit 10.1 on Form 8-K, executed on April 15, 2020 (incorporated by reference to Exhibit 10.1 on Form 8-K filed with the SEC on April 20, 2020).

Exhibit 10.1 FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (the “Amendment”) is entered into by and between ONCOSEC MEDICAL INCORPORATED (the “Company”) and DANIEL J. O’CONNOR (the “Executive”), effective as of the date of execution. WHEREAS, the Company and the Executive have entered into an executive employment agreement dated November 7

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2020 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission F

ONCS / OncoSec Medical Incorporated PRE 14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

-

90 Park Avenue New York, NY 10016 212-210-9400 | Fax: 212-210-9444 Matthew W. Mamak Direct Dial: 212-210-1256 Email: [email protected] March 30, 2020 Ms. Lisa Vanjoske Mr. Daniel Gordon Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: OncoSec Medical Inc. Form 10-K for the fiscal year ended July 31, 201

ONCS / OncoSec Medical Incorporated 10-Q - Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 000-54318 ONCOSEC MEDICAL IN

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2020 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction (Commission (IRS Employer of Inc

OncoSec Announces that the Class Action and Related Litigation Brought by Alpha Holdings Have Been Dismissed by Nevada State Court with Prejudice

Exhibit 99.1 OncoSec Announces that the Class Action and Related Litigation Brought by Alpha Holdings Have Been Dismissed by Nevada State Court with Prejudice SAN DIEGO and PENNINGTON, N.J., March 9, 2020 – OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced that the class action and related b

-

90 Park Avenue New York, NY 10016 212-210-9400 | Fax: 212-210-9444 Matthew W. Mamak Direct Dial: 212-210-1256 Email: [email protected] February 27, 2020 Ms. Lisa Vanjoske Mr. Daniel Gordon Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: OncoSec Medical Inc. Form 10-K for the fiscal year ended July 31,

ONCS / OncoSec Medical Incorporated / China Grand Pharmaceutical & Healthcare Holdings Ltd - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ONCOSEC MEDICAL INCORPORATED (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 68234L207 (CUSIP Number) China Grand Pharmaceutical & Healthcare Holdings Ltd. Attn: Chao Zhou Unit 3302, 33/F, The Center 99 Queen’s Road Central Hong Kong

ONCS / OncoSec Medical Incorporated / Altium Capital Management Lp - AMENDMENT TO FORM SC 13G Passive Investment

Page 1 of 9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Oncosec Medical Incorporated (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68234L306 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate

Registration Rights Agreement, dated as of February 7, 2020, by and between OncoSec Medical Incorporated and Grand Decade Developments Limited (incorporated by reference to Exhibit 4.1 on our Current Report on Form 8-K, filed on February 10, 2020).

Exhibit 4.1 Exhibit B REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (as it may be amended or modified from time to time, this “Agreement”) is made and entered into as of February 7, 2020 by and between OncoSec Medical Incorporated, a Nevada corporation (the “Company”), and Grand Decade Developments Limited, a British Virgin Islands limited company and a wholly owned subsidiary o

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 7, 2020 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission

Registration Rights Agreement, dated as of February 7, 2020, by and between OncoSec Medical Incorporated and Sirtex Medical US Holdings, Inc. (incorporated by reference to Exhibit 4.2 on our Current Report on Form 8-K, filed on February 10, 2020).

EX-4.2 4 ex4-2.htm Exhibit 4.2 Exhibit B REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (as it may be amended or modified from time to time, this “Agreement”) is made and entered into as of February 7, 2020 by and between OncoSec Medical Incorporated, a Nevada corporation (the “Company”), and Sirtex Medical US Holdings, Inc., a Delaware corporation (“Buyer”). WHEREAS, the Company

Amended and Restated Bylaws of OncoSec Medical Incorporated (incorporated by reference to Exhibit 3.1 on Form 8-K filed with the SEC on February 10, 2020).

Exhibit 3.1 Exhibit E AMENDED AND RESTATED BYLAWS OF ONCOSEC MEDICAL INCORPORATED TABLE OF CONTENTS Page ARTICLE 1 OFFICES 5 Section 1.1 Principal Office 5 Section 1.2 Other Offices 5 ARTICLE 2 STOCKHOLDERS’ MEETINGS 5 Section 2.1 Place of Meetings 5 Section 2.2 Annual Meetings 6 Section 2.3 Special Meetings 6 Section 2.4 Notice of Meetings 6 Section 2.5 Quorum and Voting 7 Section 2.6 Voting Righ

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

OncoSec Announces the Appointment of Robert J. DelAversano, C.P.A, as Principal Accounting Officer and Controller

Exhibit 99.1 OncoSec Announces the Appointment of Robert J. DelAversano, C.P.A, as Principal Accounting Officer and Controller SAN DIEGO and PENNINGTON, N.J., January 21, 2020 – OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, announced today the appointment of Robert J. DelAversano, C.P.A., as OncoSec’s

Financial Statements and Exhibits, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 21, 2020 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction (Commission (IRS Employer of

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated SC TO-C - - SCHEDULE TO-C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ONCOSEC MEDICAL INCORPORATED (Name of Subject Company (Issuer) ALPHA HOLDINGS, INC. (Name of Filing Persons (Offerors) Common stock ($0.0001 par value per share) (Title of Class of Securities) 68234L207 (CU

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

Press Release of Alpha Holdings, Inc. dated January 17, 2020

Exhibit 99.1 Alpha Holdings Comments on OncoSec’s Failure to Consider Superior Financing Proposal OncoSec’s Refusal to Engage with Alpha Demonstrates Need for New Leadership Alpha Clarifies OncoSec Misstatements in OncoSec Response and Reaffirms Commitment to the Success of OncoSec’s Clinical Trials Demands New Record Date to Give Stockholders a Fair Chance to Consider All Proposals Urges Stockhol

Stockholder Letter dated January 17, 2020

Exhibit 99.2 January 17, 2020 Dear Fellow OncoSec Stockholders: On January 14, 2020, Alpha delivered a binding term sheet1 to OncoSec, detailing the terms of an offer that we believe is superior to the China Grand Takeover and in the best interests of stockholders. Two days later, OncoSec rejected Alpha’s superior financing proposal, which represents $39.3 million of value compared with the $30 mi

Stocktwits posted by Alpha Holdings, Inc. on January 17, 2020

Exhibit 99.3 1. $ONCS Alpha will NOT let OncoSec run out of money before it can complete clinical trials. If its proposal were accepted, Alpha would continue to be OncoSec’s largest stockholder. Even before funding any part of the $30 million direct investment into OncoSec, Alpha would already have over $25 million invested in the company. It is completely illogical to believe Alpha would invest $

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ONCS / OncoSec Medical Incorporated DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

OncoSec Board Rejects Alpha Holdings “Proposal” and Announces New Special Meeting Date Believes Alpha’s Contingency-Laden “Proposal” is a Blatant Attempt to Mislead Shareholders into Giving Alpha Control of OncoSec Before Alpha Makes Any Cash Investm

Exhibit 99.1 OncoSec Board Rejects Alpha Holdings “Proposal” and Announces New Special Meeting Date Believes Alpha’s Contingency-Laden “Proposal” is a Blatant Attempt to Mislead Shareholders into Giving Alpha Control of OncoSec Before Alpha Makes Any Cash Investment and Potentially Without Making Any Investment At All Believes CGP/Sirtex Transaction – Which Would Provide Immediate $30 Million in F

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 16, 2020 ONCOSEC MEDICAL INCORPORATED (Exact Name of Registrant as Specified in Charter) Nevada 000-54318 98-0573252 (State or Other Jurisdiction of Incorporation) (Commission

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated SC TO-C - - SCHEDULE TO-C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ONCOSEC MEDICAL INCORPORATED (Name of Subject Company (Issuer) ALPHA HOLDINGS, INC. (Name of Filing Persons (Offerors) Common stock ($0.0001 par value per share) (Title of Class of Securities) 68234L207 (CU

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

Press Release of Alpha Holdings, Inc. dated January 15, 2020

Exhibit 99.1 INSERTING and REPLACING Alpha Holdings Sends Open Letter to OncoSec Stockholders Answering Questions on Proposed Financing Details Superior Offer to Provide $39.3 Million of Total Value to OncoSec Continues to Urge Stockholders to Vote on BLUE Proxy Card Against China Grand Takeover Encourages Stockholders Who Voted “AGAINST” on the Company’s White Card to Re-Submit Votes Using Alpha’

Binding Term Sheet delivered by Alpha Holdings, Inc. to the board of directors of OncoSec Medical Incorporated, dated January 14, 2020.

Exhibit 99.1 Hee Do Koo Chief Executive Officer Alpha Holdings, Inc. Gangnam-gu Apgujeongro 62-gil 17 -10 Seoul, Korea January 14, 2020 Oncosec Medical Incorporated 24 North Main Street Pennington, NJ 08534-2218 RE: Binding Term Sheet TO: OnocSec Medical Incorporated and the Board of Directors of OncoSec Medical Incorporated (the “Board”) Ladies and Gentlemen of the Board: Alpha Holdings, Inc., on

ONCS / OncoSec Medical Incorporated SC TO-C - - SCHEDULE TO-C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ONCOSEC MEDICAL INCORPORATED (Name of Subject Company (Issuer) ALPHA HOLDINGS, INC. (Name of Filing Persons (Offerors) Common stock ($0.0001 par value per share) (Title of Class of Securities) 68234L207 (CU

Press Release of Alpha Holdings, Inc. dated January 14, 2020

Exhibit 99.1 Alpha Holdings Makes Superior, $39.3 Million Offer to OncoSec Alpha’s Offer Would Provide Opportunity for Stockholders to Receive a Cash Premium Through a $9.3 Million Tender Offer for 35% of Shares at $2.50 per Share Alpha Would Purchase Additional $30 Million of Newly Issued Common Stock in Two Tranches Alpha’s Offer Provides $9.3 Million in Additional Value Compared with China Gran

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated DFAN14A - - DEFINITIVE ADDITIONAL MATERIALS

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 ONCOSEC MEDICAL INCORPORATED (Name of Registrant as Specified in Its Charter) Alpha Holdings, Inc.

ONCS / OncoSec Medical Incorporated / Alpha Holdings, Inc. - AMENDMENT NO. 6 TO SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 6 to SCHEDULE 13D Under the Securities Exchange Act of 1934 ONCOSEC MEDICAL INCORPORATED (Name of Issuer) Common Stock ($0.0001 par value per share) (Title of Class of Securities) 68234L207 (CUSIP Number) Hee Do Koo CEO Alpha Holdings, Inc. Gangnam-gu Apgujeong-ro 62-gil 17-10 Seoul, KOREA +82-2-517-8841 With a c